Zoledronic Acid Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
IA/0012 
A.7 - Administrative change - Deletion of 
24/01/2022 
SmPC and PL 
manufacturing sites 
IB/0011 
C.I.z - Changes (Safety/Efficacy) of Human and 
14/09/2021 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
IB/0010 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/09/2020 
23/09/2021 
SmPC 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0009 
B.II.b.1.a - Replacement or addition of a 
18/09/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IAIN/0008/G 
This was an application for a group of variations. 
19/03/2019 
28/02/2020 
Annex II and 
PL 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0007 
Transfer of Marketing Authorisation 
28/01/2019 
11/03/2019 
SmPC, 
Labelling and 
PL 
R/0006 
Renewal of the marketing authorisation. 
20/09/2018 
20/11/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Zoledronic Acid Accord in the approved indications remains 
favourable and therefore recommended the renewal of the 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
marketing authorisation with unlimited validity. 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
04/08/2017 
02/08/2018 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0004/G 
This was an application for a group of variations. 
02/08/2016 
13/07/2017 
SmPC, Annex 
II and PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0003 
B.II.e.3.b - Change in test procedure for the 
22/03/2016 
n/a 
immediate packaging of the finished product - Other 
changes to a test procedure (including replacement 
or addition) 
IB/0002 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/11/2015 
08/02/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II and PL 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
C.I.2.a - Change in the SPC, Labelling or PL of a 
10/02/2015 
08/02/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 4/4 
 
 
 
 
 
 
 
 
